These stem cell stocks could be setting up to make a big move.
Every evening on CNBC's "Mad Money," Jim Cramer tells you the stocks that are making news in the market -- and may be a good fit in your portfolio. Click here to read a recap.
How do Jim's picks fare? We keep track at Mad Money Performance.
Want to get the lingo down? Check out TheStreet.com's glossary.
|
Our experts nail it again...and again...and again. Trust them to help you maximize profits and minimize risk. |
|
![]() |
TheStreet.com RealMoney
The Astute Analysis That's a Must in This MarketSuccess nowadays is as much about avoiding losses as making money. For example, David Peltier suggested on September 4 that RealMoney members steer clear of Celanese, which he predicted would have a big dip in its $36.82 share price (it's now off by over 50%); on September 18 he said that Western Refining was also in for a fall (by mid-October it was trading at half price). Get this kind of incisive analysis from Peltier and 45 other pros when you take a free trial to RealMoney. |
![]() |
TheStreet.com Stocks Under $10
In-depth Research Will Point You to the Real WinnersFrank Curzio and his Stocks Under $10 team do extensive risk/reward analysis before recommending any stock to their members. It paid off in October when they recommended Xoma Ltd. and Epiq Systems. Within just 3 days, Xoma posted a 53% gain, Equip a 17% gain. Profit from Curzio's latest picks and get access to his model portfolio — take a free trial to Stocks Under $10 today. |